Abivax shares at the bottom of the SBF 120, down 27% over the quarter
The Paris-based biotech specializing in inflammatory diseases is falling at midday, while its index is rising. The stock remains well below its main moving averages, after several weeks of selling pressure, and bearish positions on the stock have increased.
A decline adding to the quarter's drop, testing support
Abivax shares are down 1.9% at €77.55 intraday, while the SBF 120 is up 0.43%.
The stock is among the largest declines in the index, and the quarter already shows a drop of 27.05%. This decline places the price 2.61% below the MM20 and 11.48% below the MM50, with an RSI at 40 and no oversold zone reached.
The support at €76.95 is less than 1% from the price: a level already approached in the week of October 13, when the stock had fallen below €77.10. Over the week, the loss remains limited to 1.46%, and the month is down 7.84%.
Five funds hold 5.59% of the capital in net short positions
Declared net short positions reach 5.59% of the capital, spread across five funds, according to the declarations reviewed (latest declaration on October 23). They have increased by 0.92 points over thirty days, after 4.67% one month earlier. This level signals institutional investors positioned to the downside on the stock, or seeking to hedge an exposure, without their reasons being known.
Abivax is listed in Paris and on the Nasdaq as ADSs, two lines that trade at the same price. In Paris, the support at €76.95 remains the level closest to the price.
